Summit Therapeutics Inc. (NASDAQ: SMMT) is -2.35% lower on its value in year-to-date trading and has touched a low of $0.66 and a high of $5.78 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The SMMT stock was last observed hovering at around $4.46 in the last trading session, with the day’s loss setting it -0.31% off its average median price target of $4.00 for the next 12 months. It is also -3.75% off the consensus price target high of $4.00 offered by 1 analysts, but current levels are -3.75% lower than the price target low of $4.00 for the same period.
Currently trading at $4.15, the stock is -6.04% and 41.09% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.81 million and changing -6.95% at the moment leaves the stock 152.08% off its SMA200. SMMT registered 101.46% gain for a year compared to 6-month gain of 287.85%.
The stock witnessed a 5.60% loss in the last 1 month and extending the period to 3 months gives it a 270.54%, and is -9.59% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 12.70% over the week and 20.21% over the month.
Summit Therapeutics Inc. (SMMT) has around 105 employees, a market worth around $805.06M and $1.00M in sales. Distance from 52-week low is 528.79% and -28.20% from its 52-week high. The company has generated returns on investments over the last 12 months (-103.50%).
Summit Therapeutics Inc. (SMMT) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Summit Therapeutics Inc. (SMMT) is a “Hold”. 1 analysts offering their recommendations for the stock have an average rating of 1.00, where 1 rate it as a Hold and 0 think it is a “Overweight”. 0 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Summit Therapeutics Inc. is expected to release its quarterly report on 05/15/2023.The EPS is expected to shrink by -26.70% this year.
Summit Therapeutics Inc. (SMMT) Top Institutional Holders
The shares outstanding are 148.58M, and float is at 34.00M with Short Float at 11.65%.
Summit Therapeutics Inc. (SMMT) Insider Activity
The most recent transaction is an insider purchase by DUGGAN ROBERT W,the company’sChief Executive Officer. SEC filings show that DUGGAN ROBERT W bought 94,849,203 shares of the company’s common stock on Aug 16 at a price of $0.97 per share for a total of $92.0 million. Following the purchase, the insider now owns 162.53 million shares.
Summit Therapeutics Inc. disclosed in a document filed with the SEC on Aug 16 that Zanganeh Maky (Co-CEO & President) bought a total of 5,624,702 shares of the company’s common stock. The trade occurred on Aug 16 and was made at $0.97 per share for $5.46 million. Following the transaction, the insider now directly holds 7.06 million shares of the SMMT stock.
Still, SEC filings show that on Aug 16, Zanganeh Maky (Co-CEO & President) acquired 184,430 shares at an average price of $0.97 for $0.18 million. The insider now directly holds 359,969 shares of Summit Therapeutics Inc. (SMMT).